Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Puey-Ling Chia"'
Autor:
Puey-Ling Chia, Sagun Parakh, Ming-Sound Tsao, Nhu-An Pham, Hui K. Gan, Diana Cao, Ingrid J. G. Burvenich, Angela Rigopoulos, Edward B. Reilly, Thomas John, Andrew M. Scott
Publikováno v:
Pharmaceuticals, Vol 13, Iss 10, p 289 (2020)
Epidermal growth factor receptor (EGFR) is highly overexpressed in malignant mesothelioma (MM). MAb806 is a novel anti-EGFR antibody that selectively targets a tumor-selective epitope. MAb806-derived antibody drug conjugates (ADCs), ABT-414, ABBV-221
Externí odkaz:
https://doaj.org/article/fe2d9f07976d49e8880342331b1b8d0a
Autor:
Ravindran Kanesvaran, Puey Ling Chia, Edmund Chiong, Melvin Lee Kiang Chua, Nye Thane Ngo, Samuel Ow, Hong Gee Sim, Min-Han Tan, Kiang Hiong Tay, Alvin Seng Cheong Wong, Siew Wei Wong, Puay Hoon Tan
Publikováno v:
Annals of the Academy of Medicine, Singapore. 52:135-148
Introduction: There has been a rapid evolution in the treatment strategies for metastatic castration-resistant prostate cancer (mCRPC) following the identification of targetable mutations, making genetic testing essential for patient selection. Altho
Autor:
Edward B. Reilly, Andrew M. Scott, Hui K. Gan, Thomas John, Puey-Ling Chia, Diana Cao, Joann P. Palma, Wenqing Gao, Erwin R. Boghaert, Kedar S. Vaidya, Anatol Oleksijew, Michael J. Mitten, Hugh D. Falls, Mark G. Anderson
In vivo Efficacy of ABBV-321 tumor targeting.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::677c6299c1714e54b6ad5827987299cc
https://doi.org/10.1158/1535-7163.22518654
https://doi.org/10.1158/1535-7163.22518654
Autor:
Edward B. Reilly, Andrew M. Scott, Hui K. Gan, Thomas John, Puey-Ling Chia, Diana Cao, Joann P. Palma, Wenqing Gao, Erwin R. Boghaert, Kedar S. Vaidya, Anatol Oleksijew, Michael J. Mitten, Hugh D. Falls, Mark G. Anderson
ABBV-321 (serclutamab talirine), a next-generation EGFR-targeted antibody–drug conjugate (ADC) incorporates a potent pyrrolobenzodiazepine (PBD) dimer toxin conjugated to the EGFR-targeting ABT-806 affinity-matured AM1 antibody. ABBV-321 follows th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95d6b8106485307d7fd6d8f1fb1b654d
https://doi.org/10.1158/1535-7163.c.6542049
https://doi.org/10.1158/1535-7163.c.6542049
Publikováno v:
International Journal of Urology. 30:471-472
Publikováno v:
Translational lung cancer research. 11(7)
Autor:
Sagun Parakh, Thomas John, Marzena Walkiewicz, Khashayer Asadi, Andrew M. Scott, Puey Ling Chia, Val Gebski, Carmel Murone, Prudence A. Russell, Fiona Scott, Bibhusal Thapa, Hui K Gan, Zhanqi Liu
Publikováno v:
Lung Cancer. 153:35-41
Aim Conformational forms of the epidermal growth factor receptor (EGFR) are pro‐tumorigenic. The prevalence and impact of conformational forms of EGFR in malignant mesothelioma (MM) is unknown. We investigated expression of EGFR and conformational
Publikováno v:
International journal of urology : official journal of the Japanese Urological AssociationReferences. 29(3)
Autor:
Anatol Oleksijew, Thomas John, Diana Cao, Mark Anderson, Joann P. Palma, Kedar S. Vaidya, Puey-Ling Chia, Michael J. Mitten, Hugh D. Falls, Hui K Gan, Edward B. Reilly, Andrew M. Scott, Wenqing Gao, Erwin R. Boghaert
Publikováno v:
Molecular Cancer Therapeutics. 19:2117-2125
ABBV-321 (serclutamab talirine), a next-generation EGFR-targeted antibody–drug conjugate (ADC) incorporates a potent pyrrolobenzodiazepine (PBD) dimer toxin conjugated to the EGFR-targeting ABT-806 affinity-matured AM1 antibody. ABBV-321 follows th
Publikováno v:
Expert Opinion on Drug Delivery. 16:441-451
Malignant mesothelioma (MM) is an aggressive malignancy arising from the mesothelial cells lining the pleura and other serosal membranes. It is associated with an extremely poor prognosis and has limited therapeutic options.Epidermal growth factor re